Cramer sees Pfizer’s reorganization as a ‘prelude’ to a spinoff of its consumer health-care business

Cramer sees Pfizer’s reorganization as a ‘prelude’ to a spinoff of its consumer health-care business

Pfizer’s announced reorganization could lead to an eventual spinoff of its consumer health-care business, CNBC’s Jim Cramer said Wednesday. The drug giant said it would reorganize into three units: Innovative medicines, established medicines and consumer healthcare, which it had been trying to sell since last year. The changes take effect at the start of fiscal 2019. “I think it’s a prelude to splitting up,” Cramer said on “Squawk on the Street.” Cramer, the host of…

Read More